ABSTRACT
Objective@#To investigate the level and clinical significance of miRNA-106a in non-small cell lung cancer tissues.@*Methods@#Paraffin-embedded specimens of non-small cell lung cancer tissues and adjacent tissues from 80 patients with non-small cell lung cancer from January 2012 to December 2013 in Yiwu Central Hospital were selected in this study.The real-time fluorescence quantitative polymerase chain reaction (QRT-PCR) was used to determine the level of miRNA-106a in lung cancer tissues and adjacent tissues.@*Results@#The level of miRNA-106a in non-small cell lung cancer tissues (2.42±0.23) was higher than that in adjacent tissues (1.00±0.06) (t=53.433, P=0.000). The miRNA-106a levels in lung cancer tissues of stage Ⅲ-Ⅳ, lymph node metastasis and recurrence time<6 months were high than those of the stage Ⅰ-Ⅱ, no lymph node metastasis and recurrence time ≥ 6 months(t=7.641, 11.115, 2.183, P=0.000, 0.000, 0.032). The level of miRNA-106a was not associated with age, gender, pathological type, degree of differentiation and vascular invasion (all P>0.05). The level of miRNA-106a in non-small cell lung cancer tissues was cut by 2.12.The area under the ROC curve for the diagnosis of non-small cell lung cancer was 0.823(95% CI=0.820-0.825, P=0.000), and the sensitivity was 54.37%, the specificity was 89.21%.The cumulative survival rate and progression-free survival rate of patients with low-expression of miRNA-106a in non-small cell lung cancer were higher than those with high expression of miRNA-106a (P=0.027, 0.012).@*Conclusion@#The miRNA-106a level is elevated in non-small cell lung cancer tissues.The miRNA-106a may be involved in the development of non-small cell lung cancer and is of great value in the diagnosis and prognosis evaluation of non-small cell lung cancer.
ABSTRACT
Objective To investigate the level and clinical significance of miRNA －106a in non－small cell lung cancer tissues.Methods Paraffin－embedded specimens of non －small cell lung cancer tissues and adjacent tissues from 80 patients with non －small cell lung cancer from January 2012 to December 2013 in Yiwu Central Hospital were selected in this study.The real－time fluorescence quantitative polymerase chain reaction (QRT－PCR) was used to determine the level of miRNA －106a in lung cancer tissues and adjacent tissues.Results The level of miRNA－106a in non－small cell lung cancer tissues (2.42 ±0.23) was higher than that in adjacent tissues (1.00 ± 0.06) (t＝53.433,P＝0.000).The miRNA －106a levels in lung cancer tissues of stage Ⅲ －Ⅳ,lymph node metastasis and recurrence time ＜6 months were high than those of the stage Ⅰ－Ⅱ,no lymph node metastasis and recurrence time≥6 months(t＝7.641,11.115,2.183,P＝0.000,0.000,0.032).The level of miRNA－106a was not associated with age ,gender,pathological type,degree of differentiation and vascular invasion (all P＞0.05).The level of miRNA－106a in non－small cell lung cancer tissues was cut by 2.12.The area under the ROC curve for the diagnosis of non －small cell lung cancer was 0.823(95%CI＝0.820－0.825,P＝0.000),and the sensitivity was 54.37%,the specificity was 89.21%.The cumulative survival rate and progression －free survival rate of patients with low－expression of miRNA －106a in non －small cell lung cancer were higher than those with high expression of miRNA－106a (P＝0.027,0.012).Conclusion The miRNA －106a level is elevated in non －small cell lung cancer tissues.The miRNA－106a may be involved in the development of non －small cell lung cancer and is of great value in the diagnosis and prognosis evaluation of non －small cell lung cancer.
ABSTRACT
Objective To explore the effect of miRNA‐106a(miR‐106a) expression on multidrug resistance(MDR)of gastric cancer(GC)cells and the involvement of runt‐related transcription factor 3 RUNX3.Methods The expression of miR‐106a was detected in two human gastric adenocarcinoma cell lines with MDR by immunoblotting and apoptosis assay. The sensitivity of GC cells to anticancer drugs was observed by detecting the expression of miR‐106a by using immunoblotting and PCR ,and the relationship between miR‐106a and RUNX3 was determined by luciferase activity assay.Results miR‐106a was significantly in‐creased in GC cells with MDR ,and it suppressed the sensitivity of GC cells to anticancer drugs. It could modulate MDR by tar‐geting RUNX3.Conclusion miR‐106a can induce the MDR by targeting RUNX3 in GC.